# Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

> **NCT00136916** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 635 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Inhaled Insulin
- **DRUG:** Subcutaneous insulin

## Key facts

- **NCT ID:** NCT00136916
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2002-06
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 635 (ACTUAL)
- **Why stopped:** See termination reason in detailed description.
- **Last updated:** 2010-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00136916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00136916, "Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00136916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*